Personalis, Inc. (NASDAQ:PSNL) is among the 12 Best Genomics Stocks to Invest In. Morgan Stanley Analyst Initiates Equal Weight Rating On Personalis, Inc. (PSNL) The Fly reported on December 2, 2025, that Morgan Stanley analyst Kallum Titchmarsh took over coverage of Personalis, Inc. (NASDAQ:PSNL) with an Equal Weight rating and a price objective of $11, up from $9. The firm identified several upcoming catalysts within its coverage universe starting in 2026 and outlined growing bright spots across life s ...